Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

drug-safety

18 stories tagged "drug-safety"

Infectious Disease

Gut-Vein Clots After mRNA Shots Don't Fit the 2021 Definition of a Vaccine Clot

An 80-year-old man's doctors in Japan wrote that the evidence "strongly implicated" his Moderna shot in a gut-vein clot that matched none of the 2021 criteria. The main reassuring study counted coded hospital stays after Pfizer doses and nothing else.

Nutrition & Food

A Century After Surgeons Cut Out Colons for Constipation, the Guidelines Name Kiwifruit and a Billion-Dollar Pill

Britain's dietitians now back kiwifruit, rye bread, mineral water and magnesium oxide. America's gastroenterology guideline strongly backs a billion-dollar brand-name drug, and two of its authors report ties to the company that sells it.

Cancer

The Lymphoma Combination With an 'Acceptable Safety Profile' Lost to Its Control Arm

Some oncologists want second opinions to stop steering patients away from trials. Vinay Prasad answered with venetoclax: in its randomized double-hit lymphoma cohort, estimated two-year survival was 52 percent with the drug and 72 percent without it.

Brain & Aging

One in Six School-Age American Boys Now Has an ADHD Diagnosis, and a Birthday Can Tip the Odds

Federal survey data show lifetime ADHD diagnoses among kids 5 to 17 rose from 9.9% to 13.8% since 2019, and August-born kindergartners are diagnosed a third more often than their September-born classmates.

Brain & Aging

In One Genetic Fifth of an Aspirin Trial, Dementia Fell 70 Percent and Bleeding Doubled

Among older adults genetically inclined toward high platelet counts, 1 percent on aspirin developed dementia versus 3.3 percent on placebo, in an exploratory reanalysis where major bleeding also ran 4.4 versus 2.1 percent.

Metabolic & Weight

Most of Finland's 'Low T' Men Reported Good Health 15 Years On, Even at Levels One Online Clinic Set Out to Treat

Finnish men in the bottom quarter for testosterone at 31 reported health and quality of life at 46 that didn't differ significantly from the top quarter, though their median level fell under the only treatment cutoff a 2022 secret-shopper study found among online platforms.

Cancer

Compass Plans to File a Biliary Cancer Drug Without the Survival Trial the FDA Asked For

Tovecimig plus chemotherapy shrank more biliary tract tumors than chemotherapy alone, but median survival was 8.9 months against 9.4, and 93.5 percent of the combination arm had grade 3 or worse adverse events. The FDA recommended a survival trial before filing. Compass plans to file anyway.

Cancer

Hengrui's Breast Cancer Drug More Than Doubled Progression-Free Survival While Severe Anemia Hit Four in Ten Patients

Trastuzumab rezetecan pushed median progression-free survival to 16.4 months from 6.8 on chemotherapy in 551 patients, all treated in China, while grade 3 or worse anemia reached 42.8 percent against 4.8 percent.

Drugs & FDA

GSK's Hepatitis B Drug Got a Label That Reaches Patients It Functionally Cured About One Time in 14

Below 1,000 IU/mL of surface antigen, 26 percent of treated patients reached functional cure. Between 1,000 and 3,000, a range the FDA's label also covers, GSK's own counts work out to about 7 percent, for a weekly injection boxed for serious liver reactions and low platelets.

Autoimmune & Inflammation

Arthritis From Cancer Immunotherapy Comes Back With the Same T Cell Clones

Joint fluid drawn at a first flare and again at a relapse held the same expanded T cell clones, with a stronger inflammatory signature the second time. The durable immune memory these cancer drugs are sold on has a cost in the joints.

Drugs & FDA

The First-Line Glaucoma Drop That Flatters Its Own Pressure Reading

Across 128 eyes followed at one VA clinic, the corneas that thinned most on prostaglandin drops made the pressure gauge read 3.3 mm Hg low, and those eyes lost visual field nearly twice as fast.

Autoimmune & Inflammation

Novartis Halted Eight Autoimmune CAR-T Trials After Three Deaths, Then Called the Killer a "Known Risk"

Three people in Novartis's rap-cel trials died after a runaway inflammatory syndrome, and Bristol Myers froze enrollment in its rival product. Faster manufacturing is the leading suspect, and no public report yet says how many patients got the drug.

Drugs & FDA

Kennedy's Peptide Plan Reaches the White House, and Wall Street Is Already Counting the Money

Peptides already sell on a Queens bodega shelf, so moving them into licensed pharmacies is progress. Whether it protects anyone depends on one missing rule: test each lot and report every injury.

Drugs & FDA

The FDA's Former Biologics Chief Says Public Health Can't See the Next Disaster Coming

Vinay Prasad ran the FDA's biologics center until this spring. His warning: the apparatus chases lettuce recalls and measles while a blood test for dozens of cancers heads toward Medicare with its central question unanswered.

Drugs & FDA

The FDA Approved Narcolepsy's First Orexin Agonist. Takeda's Last One Was Pulled for Liver Injury.

Takeda's oveporexton switches on the orexin receptor that narcolepsy type 1 patients can no longer signal. The company's last orexin drug was halted in 2021 after patients crossed serious liver-injury thresholds.

Drugs & FDA

For Years the Muscle Aches Were Called a Nocebo Effect. A McMaster Lab Found Statins Injuring the Muscle Cell Itself.

An estimated 7 to 29 percent of statin users report muscle pain. The flagship trial called most of it a placebo response. In mouse and human muscle cells, a McMaster team has now traced a cholesterol-independent pathway by which statins damage muscle directly.

Drugs & FDA

The FDA Office That Vets Gene Therapy Has Run Through Its Entire Top Tier in a Year

The office that decides whether gene therapies reach patients has lost its director, her deputy, and the man brought in to replace them, all inside twelve months.

Metabolic & Weight

Retatrutide's Triple-Receptor Triumph Came With a One-in-Five Skin-Sensation Signal Nobody Wanted to Linger On

Eli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbe